Oculis Holding AG
OCS, OCSAW · Pharmaceutical Preparations · EDGAR filings ↗
Grade
C66Well-funded late clinical-stage ophthalmology biopharma with multiple near-term Phase 3 readouts.
Strengths
- $103M cash (57th pct) and strong liquidity (current ratio 6.0) funding three clinical programs
- Multiple registrational catalysts: OCS-01 DME Phase 3 topline Q2 2026, Licaminlimab and Privosegtor advancing
Risks
- No approved products, net loss CHF 99M and ~5 quarters runway implies further financing
- Binary clinical/regulatory risk across all candidates; reliant on 505(b)(2) pathway for OCS-01
Notable findings
- No interest coverageInterest coverage -98.05 (cannot cover interest)
- Cash burnNegative free cash flow (-84.1M)
Key metrics
Return on equity
-50.5%
Return on assets
-41.9%
Interest coverage
-98.0×
Current ratio
6.0×
Free cash flow
-$84M
Tangible book value
$248M
Cash & investments
$103M
Cash runway
5q
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-04 | 2025-12-31 | 0001193125-26-091446 ↗ |
| 20-F | 2025-03-11 | 2024-12-31 | 0000950170-25-037224 ↗ |
| 20-F | 2024-03-19 | 2023-12-31 | 0000950170-24-033144 ↗ |
| 20-F | 2023-03-28 | 2022-12-31 | 0000950170-23-010352 ↗ |
| 20-F | 2023-03-08 | 2023-03-02 | 0001193125-23-063347 ↗ |